mutant P53 targeted TCR T-cell therapy (Affini-T Therapeutics)

N/A

Report date: 2025/03/20 15:58:13

Base Information

Drug Namemutant P53 targeted TCR T-cell therapy (Affini-T Therapeutics)
Drug Alias Nameanti-mutant P53 TCR T-cell therapy (Affini-T Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionTumor protein p53 modulatorsHuman leukocyte antigen modulators
TargetsTumor protein p53Human leukocyte antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAffini-T Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAffini-T Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A